IBIO INC (IBIO) Stock Fundamental Analysis

NASDAQ:IBIO • US4510337086

2.47 USD
+0.02 (+0.82%)
At close: Feb 24, 2026
2.48 USD
+0.01 (+0.4%)
After Hours: 2/24/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IBIO. IBIO was compared to 521 industry peers in the Biotechnology industry. IBIO has a great financial health rating, but its profitability evaluates not so good. IBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IBIO has reported negative net income.
  • In the past year IBIO has reported a negative cash flow from operations.
  • In the past 5 years IBIO always reported negative net income.
  • IBIO had a negative operating cash flow in each of the past 5 years.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • IBIO has a better Return On Assets (-31.34%) than 66.03% of its industry peers.
  • IBIO has a better Return On Equity (-35.88%) than 72.17% of its industry peers.
Industry RankSector Rank
ROA -31.34%
ROE -35.88%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.25, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
  • IBIO's Altman-Z score of -3.25 is in line compared to the rest of the industry. IBIO outperforms 46.45% of its industry peers.
  • There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.25
ROIC/WACCN/A
WACC8.67%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • IBIO has a Current Ratio of 8.39. This indicates that IBIO is financially healthy and has no problem in meeting its short term obligations.
  • IBIO has a Current ratio of 8.39. This is in the better half of the industry: IBIO outperforms 75.62% of its industry peers.
  • IBIO has a Quick Ratio of 8.39. This indicates that IBIO is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 8.39, IBIO is doing good in the industry, outperforming 75.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 8.39
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.83%, which is quite impressive.
  • IBIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.78%.
  • Measured over the past years, IBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)53.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.25%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

  • IBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.09% yearly.
  • IBIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.56% yearly.
EPS Next Y81.54%
EPS Next 2Y35.73%
EPS Next 3Y22.02%
EPS Next 5Y11.09%
Revenue Next Year-12.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IBIO's earnings are expected to grow with 22.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y22.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBIO INC

NASDAQ:IBIO (2/24/2026, 8:00:02 PM)

After market: 2.48 +0.01 (+0.4%)

2.47

+0.02 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)04-30
Inst Owners47.09%
Inst Owner Change352.22%
Ins Owners3.56%
Ins Owner Change0%
Market Cap59.03M
Revenue(TTM)400.00K
Net Income(TTM)-20.11M
Analysts85.45
Price Target4.61 (86.64%)
Short Float %18.23%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.41%
Min EPS beat(2)-31.61%
Max EPS beat(2)-5.21%
EPS beat(4)0
Avg EPS beat(4)-22.31%
Min EPS beat(4)-50.12%
Max EPS beat(4)-2.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.71%
EPS NQ rev (1m)17.5%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)0%
EPS NY rev (3m)12.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.32%
Revenue NY rev (1m)16.67%
Revenue NY rev (3m)40%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.07
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.02
BVpS2.34
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.34%
ROE -35.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.93%
Cap/Sales 9.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.39
Quick Ratio 8.39
Altman-Z -3.25
F-Score6
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)216.31%
Cap/Depr(5y)243.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.25%
EPS Next Y81.54%
EPS Next 2Y35.73%
EPS Next 3Y22.02%
EPS Next 5Y11.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-12.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
EBIT growth 1Y-30.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.93%
OCF growth 3YN/A
OCF growth 5YN/A

IBIO INC / IBIO FAQ

What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IBIO.


What is the valuation status for IBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.


Can you provide the profitability details for IBIO INC?

IBIO INC (IBIO) has a profitability rating of 1 / 10.